Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
about
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
P2860
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 December 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sequential azacitidine and len ...... a single-arm, phase 1/2 study.
@en
Sequential azacitidine and len ...... a single-arm, phase 1/2 study.
@nl
type
label
Sequential azacitidine and len ...... a single-arm, phase 1/2 study.
@en
Sequential azacitidine and len ...... a single-arm, phase 1/2 study.
@nl
prefLabel
Sequential azacitidine and len ...... a single-arm, phase 1/2 study.
@en
Sequential azacitidine and len ...... a single-arm, phase 1/2 study.
@nl
P2093
P2860
P50
P1476
Sequential azacitidine and len ...... a single-arm, phase 1/2 study.
@en
P2093
Carlos Bueso-Ramos
Courtney D DiNardo
Keyur P Patel
Naval Daver
Naveen Pemmaraju
P2860
P304
P356
10.1016/S2352-3026(14)00026-X
P50
P577
2014-12-22T00:00:00Z